By Ben Hirschler MADRID (Reuters) - A new breast cancer drug from Roche has shown "unprecedented" survival benefits in a clinical trial, boosting prospects for its widespread use in women with an aggressive form of the disease. Patients with a type of breast cancer known as HER-2 positive, which makes up about a quarter of all breast cancers, who were given Perjeta on top of older medicine Herceptin and chemotherapy lived 15.7 months longer than those on Herceptin and chemotherapy alone. “The survival improvement of nearly 16 months ... ...
via Health News Headlines - Yahoo News http://ift.tt/1noSCgA
No comments:
Post a Comment